Events

EU innovation journey '25
MAY
Mon
12
MAY
Tue
13

Starts in 2 weeks from now

Location

The Tides office

Wioślarska 8, 00-411 Warszawa, Poland
Programmes
EIE

Attachments

There is 1 attachment connected to this article.

Attachments are only accessible for people with an account on the NCP Flanders website.

Sign in (if you already have an account) or sign up.

The Polish Presidency of the Council of the EU organises a conference called EU Innovation Journey '25 on the 12th-13th of May 2025 in Warsaw, Poland.

This conference will bring together key actors from across the European innovation ecosystem to co-develop recommendations on how to bridge the innovation gap in Europe. The conference will focus on the CEE region and widening countries.

More information and registration: here.

Please find a draft version of the agenda in attachment.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.